1 de 10 sur environ 1185 communiqués.
Taconic Biosciences
RENSSELAER, N.Y., Jan. 18, 2021 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces an expansion of its immuno-oncology...
Orion Biotechnology Canada Ltd.
Genève SWITZERLAND, Jan. 14, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Holding SA., a biotechnology company focused on precision engineering small protein therapeutics, today announced that...
Onconova Therapeutics, Inc.
NEWTOWN, Pa., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products for patients...
American Oncology Network, LLC
Fort Myers, Fla., Jan. 14, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) a high-growth oncology provider partners with the Community Oncology Alliance Patient Advocacy Network (CPAN)...
Imagin Medical Inc.
VANCOUVER, British Columbia, and BOSTON, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical (CSE: IME) (OTC: IMEXF) (FRA: DPD2) (the “Company”) announces that critical milestones...
InvestorBrandNetwork (IBN)
NEW YORK, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Imagin Medical Inc. (CSE: IME) (OTCQB: IMEXF), a surgical imaging company focused on establishing a new standard of care in visualizing...
InvestorBrandNetwork (IBN)
LOS ANGELES, Jan. 13, 2021 (GLOBE NEWSWIRE) -- via InvestorWire — InvestorBrandNetwork (“IBN”), a multifaceted financial news and publishing company for private and public entities, today announces...
Florida Cancer Specialists
Fort Myers, Fla., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Florida Cancer Specialists & Research Institute (FCS) welcomes Board-certified gynecologic oncologist Jessica Stine, MD. She is caring for...
DIACCURATE
BIOKINESIS absorption by DIACCURATE occurred early December 2020Dr. Dominique BRIDON leads the new entityDIACCURATE is now developing 3 programs in cancer and immunotherapyDIACCURATE will be...
Novartis International AG
Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growthNovartis secures development and...
1 de 10 sur environ 1185 communiqués.
